2 gene editing stocks to keep on your 2024 watchlist

Key PointsBeam Therapeutics develops precision gene-editing and genetic medication for severe sickle cell disease (SCD).Beam Therapeutics performs a precision form of gene-editing called base-editing using CRISPR/Cas to make a single letter change in the DNA.Prime Medicine pioneered its Prime Editor platform to perform prime-editing, an alternative to CRISPR/Cas9, which allows for the precise replacement of a specific DNA sequence without causing insertion and deletions (indels).5 stocks we like better than ...